Tanvex BioPharma, Inc. (6541.TW)

TWD 58.5

(-3.62%)

Long Term Debt Summary of Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc.'s latest annual long term debt in 2023 was 1.56 Billion TWD , down -8.53% from previous year.
Tanvex BioPharma, Inc.'s latest quarterly long term debt in 2024 Q2 was 1.56 Billion TWD , down 0.0% from previous quarter.
Tanvex BioPharma, Inc. reported annual long term debt of 1.71 Billion TWD in 2022, up 2.65% from previous year.
Tanvex BioPharma, Inc. reported annual long term debt of 1.67 Billion TWD in 2021, up 19.4% from previous year.
Tanvex BioPharma, Inc. reported quarterly long term debt of 1.58 Billion TWD for 2024 Q1, down 0.0% from previous quarter.
Tanvex BioPharma, Inc. reported quarterly long term debt of 1.66 Billion TWD for 2023 Q2, up 0.17% from previous quarter.

Annual Long Term Debt Chart of Tanvex BioPharma, Inc. (2023 - 2013)

Historical Annual Long Term Debt of Tanvex BioPharma, Inc. (2023 - 2013)

Year	Long Term Debt	Long Term Debt Growth
2023	1.56 Billion TWD	-8.53%
2022	1.71 Billion TWD	2.65%
2021	1.67 Billion TWD	19.4%
2020	1.39 Billion TWD	414.92%
2019	271.67 Million TWD	0.0%
2018	- TWD	0.0%
2017	- TWD	0.0%
2016	- TWD	0.0%
2015	- TWD	0.0%
2014	- TWD	0.0%
2013	- TWD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	1.56 Billion TWD	0.0%
2024 Q1	1.58 Billion TWD	0.0%
2023 Q2	1.66 Billion TWD	0.17%
2023 FY	1.56 Billion TWD	-8.53%
2023 Q4	1.56 Billion TWD	-6.82%
2023 Q1	1.66 Billion TWD	-3.12%
2023 Q3	1.68 Billion TWD	1.17%
2022 Q2	1.73 Billion TWD	1.57%
2022 Q4	1.71 Billion TWD	-5.43%
2022 Q3	1.81 Billion TWD	4.66%
2022 Q1	1.7 Billion TWD	2.12%
2022 FY	1.71 Billion TWD	2.65%
2021 FY	1.67 Billion TWD	19.4%
2021 Q4	1.67 Billion TWD	-2.35%
2021 Q1	1.4 Billion TWD	0.71%
2021 Q2	1.32 Billion TWD	-5.73%
2021 Q3	1.71 Billion TWD	28.78%
2020 Q4	1.39 Billion TWD	420.61%
2020 Q1	260.77 Million TWD	-4.01%
2020 Q2	300.68 Million TWD	15.31%
2020 Q3	268.7 Million TWD	-10.64%
2020 FY	1.39 Billion TWD	414.92%
2019 Q1	345.8 Million TWD	0.0%
2019 Q2	316.47 Million TWD	-8.48%
2019 FY	271.67 Million TWD	0.0%
2019 Q4	271.67 Million TWD	-8.65%
2019 Q3	297.41 Million TWD	-6.02%
2018 Q4	- TWD	0.0%
2018 FY	- TWD	0.0%
2018 Q3	- TWD	0.0%
2018 Q2	- TWD	0.0%
2018 Q1	- TWD	0.0%
2017 Q4	- TWD	0.0%
2017 FY	- TWD	0.0%
2017 Q1	- TWD	0.0%
2017 Q2	- TWD	0.0%
2017 Q3	- TWD	0.0%
2016 Q3	- TWD	0.0%
2016 Q1	- TWD	0.0%
2016 FY	- TWD	0.0%
2016 Q2	- TWD	0.0%
2016 Q4	- TWD	0.0%
2015 Q4	- TWD	0.0%
2015 Q2	- TWD	0.0%
2015 Q1	- TWD	0.0%
2015 FY	- TWD	0.0%
2014 FY	- TWD	0.0%
2014 Q4	- TWD	0.0%
2014 Q3	- TWD	0.0%
2014 Q1	- TWD	0.0%
2013 FY	- TWD	0.0%

Peer Long Term Debt Comparison of Tanvex BioPharma, Inc.

Name	Long Term Debt	Long Term Debt Difference
Apex Biotechnology Corp.	116.19 Million TWD	-1249.731%
Sinphar Pharmaceutical Co.,Ltd.	1.49 Billion TWD	-4.965%
Panion & Bf Biotech Inc.	125.41 Million TWD	-1150.485%
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	700 Million TWD	-124.048%
GenMont Biotech Incorporation	20.11 Million TWD	-7697.996%
Abnova (Taiwan) Corporation	2.6 Million TWD	-60197.309%
Adimmune Corporation	1.91 Billion TWD	18.23%
Polaris Group	352.96 Million TWD	-344.326%
Energenesis Biomedical CO.,LTD.	- TWD	-Infinity%
UnicoCell Biomed Co., Ltd.	68.23 Million TWD	-2198.395%
PELL Bio-Med Technology Co. Ltd.	147.46 Million TWD	-963.515%